JOINN Laboratories
Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.
16 contract research organizations in our directory list a site in China. 8 report GLP capability and 5 report AAALAC accreditation. Compare services, species and accreditations below, and contact labs directly from their profiles.
China has grown into one of the largest centers of preclinical capacity, with integrated discovery providers and large toxicology facilities offering rodent, dog and nonhuman primate studies, often with competitive timelines and pricing.
Laboratories are certified for GLP by China’s National Medical Products Administration (NMPA). China is not a full adherent to the OECD Mutual Acceptance of Data system, so for studies intended to support a US or EU filing, ask about the facility’s FDA or OECD-country inspection history and how the data will be presented to your regulator.
Among the CROs listed in China, the most common services are In Vivo Efficacy, Pharmacokinetics, Toxicology and Bioanalysis. The species they most often work with are Mouse, Non-human Primate and Rat.
Showing 16 CROs with a site in China. Order rotates daily so no lab is permanently listed first.
Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.
Shanghai oncology CRO with patient-derived xenograft and other tumor models for efficacy studies.
Shanghai provider of genetically engineered rodent models with phenotyping and in vivo pharmacology services.
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Southwest China pharmacology CRO specializing in nonhuman primate efficacy, PK/PD and exploratory safety studies.
Shanghai CRO centered on nonhuman primate efficacy and safety studies, with NHP disease models across metabolism, cardiovascular, renal, neurology and ophthalmology, clinical-style imaging and interventional surgery.
Beijing-based company providing genetically engineered and humanized mouse models with in vivo pharmacology services, especially for oncology and immunology antibody programs.
Global R&D services including discovery, DMPK, toxicology, bioanalysis, and manufacturing support.
Chinese provider of genetically engineered mouse models with in vivo pharmacology services across oncology, immunology and metabolic disease.
Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.
Beijing-based preclinical CRO focused on GLP safety evaluation, with branches across China and support for biologics, nucleic acid and cell and gene therapies.
Wuhan CRO integrating NHP breeding with toxicity and safety evaluation, PK/PD, molecular imaging and bioanalysis.
For a full checklist, see our CRO selection guide.